Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes.

PubWeight™: 1.26‹?› | Rank: Top 10%

🔗 View Article (PMC 3056770)

Published in PLoS One on March 14, 2011


Rezaul Karim1, Craig Meyers, Claude Backendorf, Kristina Ludigs, Rienk Offringa, Gert-Jan B van Ommen, Cornelis J M Melief, Sjoerd H van der Burg, Judith M Boer

Author Affiliations

1: Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.

Articles citing this

Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev (2012) 1.33

Human papillomavirus (HPV) upregulates the cellular deubiquitinase UCHL1 to suppress the keratinocyte's innate immune response. PLoS Pathog (2013) 1.15

The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter. J Exp Med (2013) 1.01

Post-translational control of IL-1β via the human papillomavirus type 16 E6 oncoprotein: a novel mechanism of innate immune escape mediated by the E3-ubiquitin ligase E6-AP and p53. PLoS Pathog (2013) 1.00

Human papillomavirus E7 oncoprotein increases production of the anti-inflammatory interleukin-18 binding protein in keratinocytes. J Virol (2014) 1.00

Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response. Viruses (2013) 0.99

dsRNA Released by Tissue Damage Activates TLR3 to Drive Skin Regeneration. Cell Stem Cell (2015) 0.99

Cervical cytokines and clearance of incident human papillomavirus infection: Hawaii HPV cohort study. Int J Cancer (2013) 0.96

New Concepts for Translational Head and Neck Oncology: Lessons from HPV-Related Oropharyngeal Squamous Cell Carcinomas. Front Oncol (2012) 0.95

RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis, IL-1α release, and efficient paracrine dendritic cell activation. Oncotarget (2015) 0.91

The invisible enemy - how human papillomaviruses avoid recognition and clearance by the host immune system. Open Virol J (2012) 0.91

Biology of human papillomavirus-related oropharyngeal cancer. Semin Radiat Oncol (2012) 0.90

Role of IL-10 and TGF-β1 in local immunosuppression in HPV-associated cervical neoplasia. World J Clin Oncol (2014) 0.87

Immune therapy for human papillomaviruses-related cancers. World J Clin Oncol (2014) 0.86

CD40-mediated amplification of local immunity by epithelial cells is impaired by HPV. J Invest Dermatol (2014) 0.83

Immunotherapy of human papilloma virus induced disease. Open Virol J (2012) 0.83

The interferon-related developmental regulator 1 is used by human papillomavirus to suppress NFκB activation. Nat Commun (2015) 0.80

Cellular visualization of macrophage pyroptosis and interleukin-1β release in a viral hemorrhagic infection in zebrafish larvae. J Virol (2014) 0.80

A humanized mouse model of HPV-associated pathology driven by E7 expression. PLoS One (2012) 0.80

Human papillomavirus (HPV) deregulation of Toll-like receptor 9. Oncoimmunology (2014) 0.80

High-risk human papillomavirus targets crossroads in immune signaling. Viruses (2015) 0.79

Early Defensive Mechanisms against Human Papillomavirus Infection. Clin Vaccine Immunol (2015) 0.78

Candidate Soluble Immune Mediators in Young Women with High-Risk Human Papillomavirus Infection: High Expression of Chemokines Promoting Angiogenesis and Cell Proliferation. PLoS One (2016) 0.77

The human papillomavirus (HPV) E7 protein antagonises an Imiquimod-induced inflammatory pathway in primary human keratinocytes. Sci Rep (2015) 0.77

Canine keratinocytes upregulate type I interferons and proinflammatory cytokines in response to poly(dA:dT) but not to canine papillomavirus. Vet Immunol Immunopathol (2013) 0.77

The human papillomavirus E7 oncoprotein as a regulator of transcription. Virus Res (2016) 0.76

Tumour viruses and innate immunity. Philos Trans R Soc Lond B Biol Sci (2017) 0.76

Human papillomavirus-driven immune deviation: challenge and novel opportunity for immunotherapy. Ther Adv Vaccines (2017) 0.75

Human Papillomavirus Downregulates the Expression of IFITM1 and RIPK3 to Escape from IFNγ- and TNFα-Mediated Antiproliferative Effects and Necroptosis. Front Immunol (2016) 0.75

Integrating Inflammasome Signaling in Sexually Transmitted Infections. Trends Immunol (2016) 0.75

Manipulated microenvironment in human papilloma virus-infected epithelial cells: is the CD40-CD154 pathway beneficial for host or virus? J Invest Dermatol (2014) 0.75

Poly(I:C) induces controlled release of IL-36γ from keratinocytes in the absence of cell death. Immunol Res (2015) 0.75

After skin wounding, noncoding dsRNA coordinates prostaglandins and Wnts to promote regeneration. J Invest Dermatol (2017) 0.75

RIPK3-a predictive marker for personalized immunotherapy? Oncoimmunology (2015) 0.75

Imiquimod has strain-dependent effects in mice and does not uniquely model human psoriasis. Genome Med (2017) 0.75

Immunopathogenesis of HPV-Associated Cancers and Prospects for Immunotherapy. Viruses (2017) 0.75

Articles cited by this

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16

The KEGG resource for deciphering the genome. Nucleic Acids Res (2004) 53.05

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst (1995) 18.86

IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol (2005) 18.32

lumi: a pipeline for processing Illumina microarray. Bioinformatics (2008) 17.19

RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science (2006) 16.00

Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer (2002) 15.46

A network-based analysis of systemic inflammation in humans. Nature (2005) 12.60

The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol (2007) 12.00

RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell (2009) 10.11

Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol (2005) 9.17

WikiPathways: pathway editing for the people. PLoS Biol (2008) 8.13

RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat Immunol (2009) 6.97

The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol (2007) 6.81

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73

Model-based variance-stabilizing transformation for Illumina microarray data. Nucleic Acids Res (2008) 6.15

Papillomaviruses in the causation of human cancers - a brief historical account. Virology (2009) 5.46

GenMAPP 2: new features and resources for pathway analysis. BMC Bioinformatics (2007) 4.97

Presenting and exploring biological pathways with PathVisio. BMC Bioinformatics (2008) 4.34

IDconverter and IDClight: conversion and annotation of gene and protein IDs. BMC Bioinformatics (2007) 4.17

The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J Exp Med (2004) 4.14

Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev (1998) 4.06

Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) (2006) 3.74

Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J Invest Dermatol (2006) 3.06

The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev (2003) 2.52

Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J Virol (2000) 2.44

Immune responses to human papillomavirus. Vaccine (2006) 2.37

Synthesis of infectious human papillomavirus type 18 in differentiating epithelium transfected with viral DNA. J Virol (1997) 2.21

Anni 2.0: a multipurpose text-mining tool for the life sciences. Genome Biol (2008) 2.04

RNase 7, a novel innate immune defense antimicrobial protein of healthy human skin. J Biol Chem (2002) 1.99

Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J Virol (2001) 1.98

Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer (2002) 1.92

Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res (2004) 1.90

Toll-like receptor (TLR) expression and TLR-mediated cytokine/chemokine production by human uterine epithelial cells. Immunology (2004) 1.87

Various members of the Toll-like receptor family contribute to the innate immune response of human epidermal keratinocytes. Immunology (2005) 1.83

TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol (2007) 1.70

Toll-like receptor expression in human keratinocytes: nuclear factor kappaB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent. J Invest Dermatol (2003) 1.69

Inflammasomes in inflammatory disorders: the role of TLRs and their interactions with NLRs. Semin Immunopathol (2007) 1.54

Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem (2000) 1.52

The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology (1999) 1.46

Mechanism of PKR activation: dimerization and kinase activation in the absence of double-stranded RNA. J Mol Biol (2005) 1.44

Structural organization and regulation of the small proline-rich family of cornified envelope precursors suggest a role in adaptive barrier function. J Biol Chem (2001) 1.43

Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res (2003) 1.40

Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF. J Virol (2002) 1.32

Propagation, infection, and neutralization of authentic HPV16 virus. Virology (2004) 1.32

CORE_TF: a user-friendly interface to identify evolutionary conserved transcription factor binding sites in sets of co-regulated genes. BMC Bioinformatics (2008) 1.31

Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res (2005) 1.30

Double-stranded RNA induces an antiviral defense status in epidermal keratinocytes through TLR3-, PKR-, and MDA5/RIG-I-mediated differential signaling. J Immunol (2008) 1.30

Inactivation of the CYLD deubiquitinase by HPV E6 mediates hypoxia-induced NF-kappaB activation. Cancer Cell (2008) 1.27

A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses. Int J Cancer (2010) 1.25

Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res (2002) 1.22

Human RNase 7: a new cationic ribonuclease of the RNase A superfamily. Nucleic Acids Res (2003) 1.22

The human papillomavirus oncoprotein E7 attenuates NF-kappa B activation by targeting the Ikappa B kinase complex. J Biol Chem (2002) 1.11

Recombinant retroviruses encoding human papillomavirus type 18 E6 and E7 genes stimulate proliferation and delay differentiation of human keratinocytes early after infection. Oncogene (1992) 1.08

Interdependent transcription control elements regulate the expression of the SPRR2A gene during keratinocyte terminal differentiation. Mol Cell Biol (1996) 1.04

Innate immunity at the mucosal surface: role of toll-like receptor 3 and toll-like receptor 9 in cervical epithelial cell responses to microbial pathogens. Biol Reprod (2006) 1.03

Characterising the local immune responses in cervical intraepithelial neoplasia: a cross-sectional and longitudinal analysis. BJOG (2008) 1.01

IKK-i signals through IRF3 and NFkappaB to mediate the production of inflammatory cytokines. Cell Signal (2005) 0.96

Differentiation-regulated expression of Toll-like receptors 2 and 4 in HaCaT keratinocytes. Arch Dermatol Res (2004) 0.93

Surgery followed by persistence of high-grade squamous intraepithelial lesions is associated with the induction of a dysfunctional HPV16-specific T-cell response. Clin Cancer Res (2008) 0.92

Articles by these authors

Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med (2004) 11.61

Deep sequencing-based expression analysis shows major advances in robustness, resolution and inter-lab portability over five microarray platforms. Nucleic Acids Res (2008) 10.10

Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med (2007) 7.29

Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med (2011) 5.91

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 5.79

Phenotypically concordant and discordant monozygotic twins display different DNA copy-number-variation profiles. Am J Hum Genet (2008) 5.53

Dendritic cell immunotherapy: mapping the way. Nat Med (2004) 4.28

Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One (2008) 4.24

Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy. Nat Genet (2003) 3.60

A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature (2013) 3.46

CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum (2003) 2.68

Mutations in SWI/SNF chromatin remodeling complex gene ARID1B cause Coffin-Siris syndrome. Nat Genet (2012) 2.63

Reproducibility of high-throughput mRNA and small RNA sequencing across laboratories. Nat Biotechnol (2013) 2.53

Facioscapulohumeral muscular dystrophy is uniquely associated with one of the two variants of the 4q subtelomere. Nat Genet (2002) 2.42

Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease. Am J Hum Genet (2005) 2.40

Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med (2011) 2.39

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer (2008) 2.31

Human keratinocytes are efficiently immortalized by a Rho kinase inhibitor. J Clin Invest (2010) 2.19

Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet (2003) 2.17

An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell (2011) 2.14

Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res (2008) 2.06

Deep sequencing to reveal new variants in pooled DNA samples. Hum Mutat (2009) 2.04

Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res (2009) 2.04

M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol (2011) 2.02

MHC II in dendritic cells is targeted to lysosomes or T cell-induced exosomes via distinct multivesicular body pathways. Traffic (2009) 1.98

High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res (2007) 1.96

Advances in Duchenne muscular dystrophy gene therapy. Nat Rev Genet (2003) 1.96

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol (2002) 1.93

Copy number variation in regions flanked (or unflanked) by duplicons among patients with developmental delay and/or congenital malformations; detection of reciprocal and partial Williams-Beuren duplications. Eur J Hum Genet (2006) 1.93

Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res (2004) 1.90

Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA (2007) 1.78

An immune response network associated with blood lipid levels. PLoS Genet (2010) 1.74

Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul Disord (2002) 1.72

Frequency of new copy number variation in humans. Nat Genet (2005) 1.71

Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol (2011) 1.71

Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A (2010) 1.67

In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med (2009) 1.66

Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol (2002) 1.66

Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res (2008) 1.66

ROS quenching potential of the epidermal cornified cell envelope. J Invest Dermatol (2011) 1.64

Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA (2009) 1.60

Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. Cancer Res (2010) 1.59

Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood (2008) 1.56

Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol (2009) 1.56

Comprehensive detection of genomic duplications and deletions in the DMD gene, by use of multiplex amplifiable probe hybridization. Am J Hum Genet (2002) 1.55

Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res (2008) 1.54

CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol (2007) 1.54

Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci U S A (2007) 1.53

Small N-terminal mutant huntingtin fragments, but not wild type, are mainly present in monomeric form: Implications for pathogenesis. Exp Neurol (2005) 1.53

Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet (2003) 1.52

Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res (2004) 1.51

Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. Mol Ther (2008) 1.48

Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides. Mol Ther (2004) 1.46

Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas. J Immunol (2002) 1.46

Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res (2003) 1.40

Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res (2011) 1.39

Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons. Mol Ther (2006) 1.38

Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res (2005) 1.38

Can subtle changes in gene expression be consistently detected with different microarray platforms? BMC Genomics (2008) 1.36

Hierarchical modeling for rare event detection and cell subset alignment across flow cytometry samples. PLoS Comput Biol (2013) 1.35

A common reference for cDNA microarray hybridizations. Nucleic Acids Res (2002) 1.35

CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci U S A (2002) 1.34

Preclinical PK and PD studies on 2'-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol Ther (2010) 1.32

Propagation, infection, and neutralization of authentic HPV16 virus. Virology (2004) 1.32

CORE_TF: a user-friendly interface to identify evolutionary conserved transcription factor binding sites in sets of co-regulated genes. BMC Bioinformatics (2008) 1.31

The Nlrp3 inflammasome regulates acute graft-versus-host disease. J Exp Med (2013) 1.31

Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res (2005) 1.30

Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J Immunol (2004) 1.29

Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res (2013) 1.28

Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells. J Exp Med (2007) 1.28